Immune checkpoint silencing using RNAi-incorporated nanoparticles enhances antitumor immunity and therapeutic efficacy compared with antibody-based approaches

BACKGROUND: Cytotoxic CD8(+) T cell-based cancer immunotherapy has been extensively studied and applied, however, tumor cells are known to evade immune responses through the expression of immune checkpoints, such as programmed death ligand 1 (PD-L1). To overcome these issues, antibody-based immune c...

Descripción completa

Detalles Bibliográficos
Autores principales: Won, Ji Eun, Byeon, Youngseon, Wi, Tae In, Lee, Chan Mi, Lee, Ju Hyeong, Kang, Tae Heung, Lee, Jeong-Won, Lee, YoungJoo, Park, Yeong-Min, Han, Hee Dong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Basic Tumor Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8886443/
https://www.ncbi.nlm.nih.gov/pubmed/35228265
http://dx.doi.org/10.1136/jitc-2021-003928

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8886443/
https://www.ncbi.nlm.nih.gov/pubmed/35228265
http://dx.doi.org/10.1136/jitc-2021-003928

Ejemplares similares